Standard
Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial. / Fjordén, Karin; Ekberg, Sara; Kuric, Nevzeta; Smedby, Karin E.; Lagerlöf, Ingemar; Larsen, Thomas S.; Jørgensen, Judit M.; de Nully Brown, Peter; Jerkeman, Mats.
In:
British Journal of Haematology, Vol. 196, No. 2, 2022, p. 437-440.
Research output: Contribution to journal › Comment/debate › Research › peer-review
Harvard
Fjordén, K, Ekberg, S, Kuric, N, Smedby, KE, Lagerlöf, I, Larsen, TS, Jørgensen, JM
, de Nully Brown, P & Jerkeman, M 2022, '
Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial',
British Journal of Haematology, vol. 196, no. 2, pp. 437-440.
https://doi.org/10.1111/bjh.17792APA
Fjordén, K., Ekberg, S., Kuric, N., Smedby, K. E., Lagerlöf, I., Larsen, T. S., Jørgensen, J. M.
, de Nully Brown, P., & Jerkeman, M. (2022).
Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial.
British Journal of Haematology,
196(2), 437-440.
https://doi.org/10.1111/bjh.17792Vancouver
Fjordén K, Ekberg S, Kuric N, Smedby KE, Lagerlöf I, Larsen TS et al.
Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial.
British Journal of Haematology. 2022;196(2):437-440.
https://doi.org/10.1111/bjh.17792Author
Fjordén, Karin ; Ekberg, Sara ; Kuric, Nevzeta ; Smedby, Karin E. ; Lagerlöf, Ingemar ; Larsen, Thomas S. ; Jørgensen, Judit M. ; de Nully Brown, Peter ; Jerkeman, Mats. / Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial. In: British Journal of Haematology. 2022 ; Vol. 196, No. 2. pp. 437-440.
Bibtex
@article{6aaaab54946246828f07ca759b7d4808,
title = "Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial",
author = "Karin Fjord{\'e}n and Sara Ekberg and Nevzeta Kuric and Smedby, {Karin E.} and Ingemar Lagerl{\"o}f and Larsen, {Thomas S.} and J{\o}rgensen, {Judit M.} and {de Nully Brown}, Peter and Mats Jerkeman",
note = "Funding Information: We thank all the patients and the participating centres for their contribution. We thank Gilead for contribution with research grant and supply of study drug idelalisib. ",
year = "2022",
doi = "10.1111/bjh.17792",
language = "English",
volume = "196",
pages = "437--440",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",
}
RIS
TY - JOUR
T1 - Idelalisib in relapsed/refractory diffuse large B-cell lymphoma
T2 - results from a Nordic Lymphoma Group phase II trial
AU - Fjordén, Karin
AU - Ekberg, Sara
AU - Kuric, Nevzeta
AU - Smedby, Karin E.
AU - Lagerlöf, Ingemar
AU - Larsen, Thomas S.
AU - Jørgensen, Judit M.
AU - de Nully Brown, Peter
AU - Jerkeman, Mats
N1 - Funding Information:
We thank all the patients and the participating centres for their contribution. We thank Gilead for contribution with research grant and supply of study drug idelalisib.
PY - 2022
Y1 - 2022
U2 - 10.1111/bjh.17792
DO - 10.1111/bjh.17792
M3 - Comment/debate
C2 - 34435356
AN - SCOPUS:85113305805
VL - 196
SP - 437
EP - 440
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 2
ER -
